【Abstract】Objective To study the effects of arsenic trioxide (As2O3) on inhibiting the proliferation of hepatic carcinoma cell lines. Methods To detect the inhibiting rate of As2O3 and other 6 kinds of anticancer drugs (such as, NOV, ADM, MMC, 5-Fu, DDP and CTX) on hepatic carcinoma cell lines BEL-7404 and SMMC-7721 by using MTT assay. Results As compared with other 6 kinds of anticancer drugs, the inhibiting rate of As2O3 was the highest one (P＜0.01 or P＜0.05). The inhibiting rates of As2O3 in the groups with the concentration above 1.0 μg/ml were no different (P＞0.05). Conclusion As2O3 could inhibit hepatic carcinoma cell lines BEL-7404 and SMMC-7721 effectively in vitro. Drug sensitivity tests of different concentration’s As2O3 should be done in order to select the minimal and effective concentration of arsenic trioxide and reduce the side effects of arsenic trioxide.
ObjectiveTo introduce economic evaluation methods for anticancer-drugs with basket trial design, and to provide references for related research and decision-making. MethodsA case analysis was conducted on economic evaluation methods for anticancer-drugs with basket trial design, which was issued by Canadian Agency for Drugs and Technologies in Health (CADTH) in the Economic Guidance Report. Moreover, both the advantages and disadvantages of the methods were analyzed in accordance with the characteristics of basket trials. ResultsPooled analysis and tumor-specific analysis were two methods frequently employed in the case analysis. However, great uncertainties were available in both of them. The uncertainty of the former was mainly reflected in the heterogeneity of the targeted population, while the uncertainty of the latter was mainly shown in the insufficient sample size of the subgroup. ConclusionCurrently, economic evaluation methods for anticancer-drugs with basket trial design are immature. Thus, researchers are required to explore the methods of innovation evaluation with lower uncertainty; reimbursement decision-makers should fully consider the uncertainty of evaluation results and enterprises should collect the real-world data for the demands of evaluation to promote the reasonable allocation of healthcare resources in China.